IN8bio rises on early-stage data from cancer therapy

IN8bio

11/02/2025 16:44

** Shares of the New York-based drug developer IN8bio
 INAB.O  rises 17.5% to 31 cents 
    ** Co says early-stage trial showed its experimental cancer
therapy helped all 9 patients with a type of blood cancer remain
in complete remission
    ** Co's therapy, INB-100, also helped increase survival
rates of patients compared to historical data and the time they
lived without their cancer worsening
    ** INAB was testing its therapy to treat acute myeloid
leukemia, a cancer of the blood and bone marrow 
    ** INB-100 uses gamma-delta T cells, that are rarely found
in secondary lymphoid organs and play a role in helping control
cancer activity, to target the disease 
    ** Patients treated with INB-100 also showed prolonged and
durable decrease in symptoms of their cancer beyond one year
    ** In the last 12 months, INAB has fallen 70.27% 

 (Reporting by Siddhi Mahatole)
 ((siddhiprabhanjan.mahatole@thomsonreuters.com))